Can radiation-recall predict long lasting response to immune checkpoint inhibitors?
- 22 September 2020
- journal article
- research article
- Published by Elsevier BV in Radiotherapy and Oncology
- Vol. 154, 125-127
- https://doi.org/10.1016/j.radonc.2020.09.037
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Clinical characteristics of nivolumab-induced radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real-world analysis of 669 patients.Journal of Clinical Oncology, 2020
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab TherapyJAMA Oncology, 2019
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of Clinical Oncology, 2017
- Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialThe Lancet Oncology, 2017
- Nivolumab induced radiation recall pneumonitis after two years of radiotherapyAnnals Of Oncology, 2017
- Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib TherapyJAMA Dermatology, 2016
- Vemurafenib and RadiosensitizationJAMA Dermatology, 2013
- Targeted therapy-induced radiation recallEuropean Journal Of Cancer, 2013
- Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?Annals Of Oncology, 2011